Silver Spring, Maryland—(ENEWSPF)—August 6, 2018
By: Michael Felberbaum
The U.S. Food and Drug Administration today issued new scientific recommendationsaimed at encouraging more widespread innovation and development of novel medication-assisted treatment (MAT) drugs for the treatment of opioid use disorder (OUD). New draft guidance issued today outlines new ways for drug developers to consider measuring and demonstrating the effectiveness and benefits of new or existing MAT products. This new draft guidance is part…
